INmune Bio announced on October 21, 2026, that it had signed a services agreement with Uniphar Durbin Ireland Limited to prepare international access, distribution and commercialization for Ebstrocel, its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The Ebstrocel agreement initially targets named-patient access in selected European, Middle Eastern and North African markets; it does not constitute regulatory approval.
Key Takeaways
- Initial access depends on local law and country-specific statements of work.
- Uniphar could provide distribution, market-access and operational services without INmune Bio building each capability locally.
- A separate regulatory update targets a full UK application in early February 2027, replacing an earlier rolling-submission plan.
Table of Contents
- Ebstrocel agreement starts with individual-patient access
- Uniphar provides infrastructure for a staged rollout
- Updated UK filing plan replaces the earlier timetable
- Conclusion
Ebstrocel agreement starts with individual-patient access
The master services agreement establishes a framework rather than an immediate broad commercial launch. INmune Bio intends to begin with named-patient supply where permitted, with the relationship potentially expanding across Europe and into other territories by mutual agreement.
Named-patient access may allow physicians to request treatment for individual eligible patients before local marketing approval or broad commercial availability. Implementation still requires compliance with each country's rules and an agreed statement of work.
Ebstrocel, also called pobistrocel, is a pooled, allogeneic mesenchymal stromal cell therapy derived from human umbilical cord. It remains investigational and has not been approved by the FDA, the UK MHRA, the EMA or any other regulator.
| Item | Details |
|---|---|
| UK preparatory milestone | Final pre-application package submitted to the MHRA on October 20, 2026. |
| Expected MHRA response window | Three to six months after full submission, subject to validation, review and requests for additional information. |
| Potential UK approval | Mid-2027, subject to MHRA review; not an approval commitment. |
| Planned US filing | Biologics License Application targeted for the second quarter of 2027, subject to FDA meeting feedback. |
Uniphar provides infrastructure for a staged rollout
Depending on the country-specific agreements, Uniphar may provide regulatory feasibility assessments, market access, storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and shipment tracking.
Chief Executive Officer David Moss said the arrangement gives INmune Bio access to established capabilities without having to build them country by country. Management views that approach as a capital-efficient way to pursue early access while developing physician relationships and treatment-center experience.
The practical distinction is between having distribution infrastructure available and having permission to sell broadly. Wider commercialization remains dependent on regulatory approvals, pricing and reimbursement in individual markets.
Updated UK filing plan replaces the earlier timetable
INmune Bio's October 21 regulatory update sets out a revised UK submission strategy: the company now targets a complete marketing authorization application in early February 2027, replacing a sequential rolling submission previously planned to begin in late 2026.
The company attributed the change to faster-than-expected manufacturing progress. It believes submitting the complete package together could bring potential UK approval forward by approximately six weeks, but that remains a management expectation subject to MHRA review.
INmune Bio also said it was prioritizing a US application ahead of an EMA submission. Its planned US filing depends on feedback from an FDA meeting, so neither the access agreement nor the regulatory timetable guarantees approval.
Conclusion
The agreement prepares an international delivery network rather than confirming commercial availability. The next stated UK milestone is the planned full application in early February 2027, while named-patient access depends on country-level arrangements and legal requirements.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
